If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
ONCOLOGY
ISSN 2054-619X November 2013 • emjreviews.com
INSIDE
Review of the
European Cancer Congress 2013
Amsterdam, the Netherlands
ECCO-ESMO-ESTRO
NOW LICENSED
A NEW First-Line BRAF Inhibitor
TAFINLAR is indicated in monotherapy for the treatment of adult patients
with unresectable or metastatic melanoma with a BRAF V600 mutation
Before taking TAFINLAR, patients must have confirmation of tumour BRAF V600 mutation using a validated test
Prescribing Information
(Please refer to full SmPC before prescribing)
Tafinlar ® (dabrafenib) 50mg and 75mg capsules. Each capsule contains
dabrafenib mesilate, equivalent to 50mg and 75mg of dabrafenib, respectively.
Indication In monotherapy for adults with unresectable or metastatic melanoma
with a BRAF V600 mutation. Dosage and administration Before
ONCOLOGY ISSN 2054-619X
NOW LICENSED A NEW First-Line BRAF Inhibitor
Treatment with TAFINLAR was proven to significantl
CONTENTS EDITORIAL BOARD.......................
ONCOLOGY METASTASIS OF DUCTAL BREAST CARCINOMA
Editorial Board ONCOLOGY Prof Ross Abrams Prof
European Medical Journal Oncology - November 2013
For most metastatic colorectal cancer patients,
PRESCRIBING INFORMATION Refer to Avastin Summary
Foreword Prof Bill Heald, CBE
1. Basil Morson, Personal communic
ECC CONGRESS 2013 RAI EXHIBITION AND CONVENTION C
Welcome to the European Medical Journal review of
ECC CONGRESS 2013 RAI EXHIBITION AND CONVENTION C
cancer screening programmes across th
ECC CONGRESS 2013 RAI EXHIBITION AND CONVENTION C
Ipilimumab can increase survival rates in melanom
ECC CONGRESS 2013 RAI EXHIBITION AND CONVENTION C
Diabetics beware: increased risks of breast and c
ECC CONGRESS 2013 RAI EXHIBITION AND CONVENTION C
Aspirin improves colon cancer survival A CELL-S
ECC CONGRESS 2013 RAI EXHIBITION AND CONVENTION C
Younger patients are at higher risk of detrimenta
ECC CONGRESS 2013 RAI EXHIBITION AND CONVENTION C
Paving the way for personalised treatments THE
ECC CONGRESS 2013 RAI EXHIBITION AND CONVENTION C
Anti-cancer drug T-DM1 may benefit women with adva
ECC CONGRESS 2013 RAI EXHIBITION AND CONVENTION C
Cediranib improves survival in recurrent ovarian
ECC CONGRESS 2013 RAI EXHIBITION AND CONVENTION C
Everolimus: new hope for advanced papillary kidne
EVIDENCE-BASED TREATMENT PLANNING IN mCRC:
fluorouracil and oxaliplatin) together with t
Evidence-Based Treatment Planning
Dr Gill considered alternative scenarios for
III study (HORIZON III). J Clin Oncol. 2012
38. Sobrero AF. Final results from study metas
THE FUTURE OF CHRONIC LYMPHOCYTIC LEUKAEMIA
monotherapy. The results showed that there was no
to be treated with chemoimmunotherapy
Table 1. Addition of rituximab to fludarabine and
A Phase III trial, CLL10 study, of the GCLLSG25 e
The Economic Burden of CLL Treatment Now and in t
Table 3. The present drug costs for chroni
100 80 Patients (%) 60 40 20 0 Cause
is known that they simply will not survive
randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;
EXTREME HYPOFRACTIONATED IMAGE-GUIDED RADIO
primary advantage, compared to conventional 3
where needles remain inserted into the pati
Table 1. Extreme hypofractionation studies. Autho
Figure 1.a Figure 1.b
Right- Lateral (cm) Left + 2.0 1.5 1.0 0.5 0.0 -
of treatment have been confirmed for volumes
radiotherapy for localized prostate cancer:
PROSTATE CANCER AND INFLAMMATION:
angiogenesis, and evasion from apopto
pro-inflammatory PDCD4, enhances the production of
CONCLUDING REMARKS Nowadays it is well-known
miRNA expression studies published where
ROLE OF POSITRON EMISSION TOMOGRAPHY WITH FLUO
receptor expression. In addition, the integr
significant advantages of FDG PET/CT over bone sci
FDG PET/CT detected 75% histopathologically-
Figure 4. A 70-year-old patient with rising PSA l
NOVEL PET TRACERS FOR PROSTATE CANCER In recent
2003;70:311-5. 24. Schoder H et al. 2-[18F]fl
GENOMIC TESTING IN INTERNATIONAL GUIDELINES Peter
latest St. Gallen consensus lies in the midst of
most recently. The authors asserted that to
Low RS (<18) Intermediate RS (18-30) High RS (≥31
multigene array. The 21-gene RS was judged to be
IB and is mentioned as the only multigene array (
REFERENCES 1. Sorlie T. Gene expression patterns
AF_RCCM_LANCETONCOLOGY_21x27.pdf 1 11/1/13
METASTASIS OF DUCTAL BREAST CARCINOMA TO THE
Figure 1. Histological examination of the vagina
Although the diagnosis of this breast tumour was
Involvement of the bone generally suggests
NEW CERVICAL CANCER SCREENING GUIDELINES
the HPV test in screening, and particularly how t
cannot be used to estimate the effect
account the impact of vaccinated cohorts on
A B 6 months cytology HPV- 5yy HPV/ cytology
Table 1. Synthesis of the recommendations of the
Table 2. Document conclusions, evidence statement
Netherlands The Committee concludes
Looking at the last 20 years of cervical cancer s
2011;155(10):687-97. 19. Ronco G et al. Heal
INTENSITY-MODULATED RADIOTHERAPY IN THE TREATME
of IMRT is increasingly aimed at generating
Table 1. Intensity-Modulated Radiotherapy with co
Table 2. Dose-esclation Intensity-Modulated Radio
Table 3. Intensity-Modulated Radiotherapy wit
The dose-limiting toxicities were neutropaeni
Data of 39 patients with LAPC treated with RT usi
9. Fuss M et al. Image-guided intensity- modulate
KEY ADVANCES IN THE SYSTEMIC THERAPY FOR SOFT TIS
combination is more active in uterine LMS and und
subgroup analyses, and was independent of the num
(8%), and dyspnoea, fatigue, nausea, an
Table 1. Important ongoing clinical studies in so
Mifamurtide (Mepact), also known as liposoma
18. Demetri GD et al. Results of an intern
CALL FOR PAPERS IF YOU ARE INTERESTED IN SUBMITT
YOGA AS TREATMENT FOR INSOMNIA AMONG CANCER PA
YOGA A Holistic Mind-Body Mode of Exercise Yoga i
Table 1. Published Phase I-III clinical research
Sleep NC Measure(s): Pittsburgh Sleep Quality In
The interventions were deemed safe and
drift. The yoga prescription in the interve
Clinicians can provide important information
Table 3. Examples of exercise contraindications a
this study and the other smaller Phase I-II studi
and sleep quality in a randomized trial of the ef
WHAT’S NEW Innovative organ creation: Another ste
ONCOLOGY Cancer costs multi-billions to EU “We a
WHAT’S NEW Internet connects cancer patients CAN
ONCOLOGY UK PM announces continuation of Cancer D
WHAT’S NEW Continuity in primary care could accel
ONCOLOGY Is radiotherapy the way forward for blad
WHAT’S NEW Blood pressure drug improves effects o
Conference highlights:
BUYER’S GUIDE AAAS/Science Agendia Altos Solutio
OncoDNA OncoGenex Pharmaceuticals, Inc. Orfit Indu
Genomic Health is a molecular diagnostics company
SUBSCRIBE TO THE EMJ NEWSLETTER www.news.emjrevie
UPCOMING EVENTS Gastrointestinal Cancers Sympo
ONCOLOGY 13th ESO-ESMO Masterclass in Clinical
SUBSCRIBE TO RECEIVE THE LATEST PUBLICATIONS NEW